An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride Event to End Pancreatic Cancer
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
RenovoRx, a biopharmaceutical company focused on targeted cancer therapies, announces its participation as a Silver Sponsor for the PurpleStride Silicon Valley event on April 30, aimed at combating pancreatic cancer. The event will resume in-person fundraising after two years of virtual events. Pancreatic cancer remains a critical health issue, with a five-year survival rate of just 11% and 62,000 diagnoses expected in 2022. RenovoRx aims to improve outcomes through its RenovoTAMP therapy platform and is advancing its lead product, RenovoGem, in clinical trials.
Positive
Participation in PurpleStride event enhances brand visibility and community engagement.
Development of RenovoGem is positioned to address a significant unmet medical need in pancreatic cancer treatment.
Negative
None.
RenovoRx Raises Funds and Awareness to Fight World’s Toughest Cancer
LOS ALTOS, Calif.--(BUSINESS WIRE)--
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, announced today it will join the Pancreatic Cancer Action Network (PanCAN) as a Silver Sponsor of the organization’s PurpleStride® Silicon Valley event to end pancreatic cancer.
In order to help improve patient outcomes, RenovoRx employees and their families have united to create Team RenovoRx with a goal to support PanCAN’s urgent mission to save lives. After two years of virtual fundraising events due to the ongoing pandemic, PurpleStride Silicon Valley 2022 will be back in person at Discovery Meadow in downtown San Jose, CA on Saturday, April 30.
“All of us at RenovoRx proudly support the PurpleStride walk, which improves pancreatic cancer awareness across the country,” said Shaun Bagai, CEO of RenovoRx. “We’re continually energized by the people we meet in this important cause and are dedicated to advancing treatment options for patients impacted by pancreatic cancer.”
For the first time ever, Silicon Valley’s PurpleStride walk is coordinated with nearly 60 other communities across the nation for one nationally synchronized PanCAN PurpleStride event. City-by-city, thousands of supporters will walk the nation in solidarity to raise national awareness and much-needed funds for pancreatic cancer. Funds raised through this nationwide movement fuel life-changing programs and services for pancreatic cancer patients and their families.
“By taking action locally, we have the opportunity to make a difference in the lives of pancreatic cancer patients nationwide,” said Ariane Chappel, chair of PanCAN’s Silicon Valley affiliate. “We are grateful to RenovoRx’s commitment to raise vital funds and awareness to support the pancreatic cancer community through this important event.”
Pancreatic cancer is the world’s deadliest cancer with a five-year survival rate of just 11 percent. In 2022, more than 62,000 Americans will be diagnosed with pancreatic cancer and nearly 50,000 will die from the disease, making it the third leading cause of cancer-related death in the U.S.
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.
RenovoRx’s patent portfolio includes seven U.S. patents for its technology. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.
RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.
The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive.
Company Contact:
RenovoRx, Inc. Shaun R. Bagai, CEO
Christopher J. Lehman, CFO
Investor Contact:
KCSA Strategic Communications Valter Pinto or Jack Perkins T: 212-896-1254
renovorx@kcsa.com
Media Contact:
Knight Marketing Communications, Ltd. Kevin Knight T: 206-451-4823
kknightpr@gmail.com
Source: RenovoRx, Inc.
FAQ
What is RenovoRx's involvement in the PurpleStride event?
RenovoRx is a Silver Sponsor for the PurpleStride Silicon Valley event on April 30, aimed at raising awareness and funds to fight pancreatic cancer.
What is RenovoGem and its significance for RenovoRx?
RenovoGem is RenovoRx's lead product candidate, a combination of gemcitabine with a patented delivery system, currently studied in the Phase 3 TIGeR-PaC trial for treating locall advanced pancreatic cancer.
What are the statistics on pancreatic cancer mentioned in the press release?
In 2022, it is expected that over 62,000 Americans will be diagnosed with pancreatic cancer, with nearly 50,000 deaths, making it the third leading cause of cancer-related deaths in the U.S.
